Ecority Will Catalyze a National Network of Credit Unions and State-Chartered Green Banks to Deploy Clean Energy Projects Through the EPA Greenhouse Gas Reduction Fund
SAN ANTONIO–(BUSINESS WIRE)–Ecority, a nonprofit coalition of credit unions and state-chartered green banks, has applied to the EPA-administered Greenhouse... Read more.
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established... Read more.
Keysight Completes the Acquisition of a Controlling Block of Shares of ESI Group and Confirms its Intent to Launch a Tender Offer for the Remaining Outstanding Shares
Completion of Keysight’s acquisition of a controlling block representing 50.6% of the share capital of ESI Group. Intent to file a public tender offer (“offre... Read more.
Agilysys Announces Mandatory Conversion Date for Series A Convertible Preferred Stock
ALPHARETTA, Ga.–(BUSINESS WIRE)–Agilysys, Inc. (Nasdaq: AGYS) announced today that it has delivered a notice of mandatory conversion to the holders of... Read more.
Hudson Therapeutics, Inc. Appoints Janice Marie McCourt as co-Chief Executive Officer and Board Member
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Hudson Therapeutics, Inc., a biotechnology company specializing in anti-inflammatory and immuno-oncology... Read more.
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments... Read more.
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments... Read more.
Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif.–(BUSINESS WIRE)–$LBPH #Epilepsy—Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused... Read more.
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
Promising anti-tumor activity in heavily pretreated clear cell renal cell carcinoma (ccRCC) patients Objective response rate (ORR) of 21.4% and disease control rate... Read more.
Cimeio Therapeutics Announces Poster Presentations at ASH 2023
– CD45 ADC effectively eliminates AML cells in vivo, while CD45 epitope-edited healthy cells were shielded from ADC depletion – BASEL, Switzerland &... Read more.